Arbutus Biopharma (ABUS) and Gritstone Oncology have signed a collaboration and license agreement under which Arbutus will deploy its proprietary lipid nanoparticle (LNP) technology to deliver Gritstone’s RNA-based neoantigen immunotherapy products.

Under the terms of the deal, Gritstone obtains worldwide access to Arbutus’ portfolio of proprietary and clinically validated LNP products and associated intellectual property. Gritstone will pay Arbutus an upfront payment, payments for achievement of development, regulatory, and commercial milestones, as well as royalties.

Gritstone will also reimburse Arbutus for conducting technology development and providing manufacturing and regulatory support for Gritstone’s product candidates. The license is specifically directed to the novel RNA-based platform for neoantigen immunotherapies.


Fatal error: Call to undefined function printFooterForm() in /home4/mando123/public_html/collinscourier.com/wp-content/themes/alpha/single.php on line 57